NovoCure Limited (NVCR)

NovoCure Limited is trading at $17.50, down 0.85% on the session. The 50 day average sits at $16.46 and the 200 day at $14.20, which puts the stock in a uptrend. RSI is at 55.4, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $16.78 with resistance near $17.83, so that band frames the current range. Average daily movement is roughly $0.90, or about 5.1% of the share price, which is what any stop placement has to allow for. The overall health score of 81 out of 100 combines a trend score of 93, momentum of 88 and a risk score of 52.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.